New CLL Treatment Paradigm Nears In EU For AbbVie
EMA OKs New Indication For Venclyxto
Executive Summary
The first chemotherapy-free, first-line treatment for chronic lymphocytic leukemia where dosing can be completed in one year has received the thumbs up by the European Medicines Agency.
You may also be interested in...
AbbVie’s Venclexta Fails In Combo AML Trial
AbbVie’s Venclexta failed to show a significant improvement in the primary endpoint of overall survival in the Phase III VIALE-C for AML, but there was numerical improvement. Its setback is good news for Pfizer’s rival Daurismo, analysts said.
EU Firsts Beckon For Alnylam & Novo; Wins For A Raft Of Others
A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.